MedPath
Found 9 clinical trials|View Analysis
Sort by:

Safety and Efficacy of PRG-1801 in Recurrent/Refractory Immune Thrombocytopenia (ITP)

Early Phase 1
Recruiting
Conditions
Immune Thrombocytopenia
Interventions
Drug: PRG-1801
First Posted Date
2024-07-25
Last Posted Date
2024-12-04
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
9
Registration Number
NCT06519565
Locations
🇨🇳

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP

Not yet recruiting
Conditions
ITP - Immune Thrombocytopenia
Chronic ITP
Refractory ITP
Interventions
First Posted Date
2022-11-14
Last Posted Date
2023-01-13
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
47
Registration Number
NCT05613296

A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP

Phase 2
Conditions
Immune Thrombocytopenia
Bruton's Tyrosine Kinase
Interventions
First Posted Date
2021-08-25
Last Posted Date
2021-08-25
Lead Sponsor
Shandong University
Target Recruit Count
40
Registration Number
NCT05020288

A Clinical Trial of the Low Dose Chidamide in the Management of Refractory ITP

Phase 2
Conditions
Thrombocytopenia
Interventions
First Posted Date
2019-02-12
Last Posted Date
2019-02-12
Lead Sponsor
Shandong University
Target Recruit Count
30
Registration Number
NCT03838354
Locations
🇨🇳

Qilu hospital, Shandong University, Jinan, Shandong, China

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Conditions
Immune Thrombocytopenic Purpura
First Posted Date
2017-12-06
Last Posted Date
2018-08-01
Lead Sponsor
Rigel Pharmaceuticals
Registration Number
NCT03363334

Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

Phase 3
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
First Posted Date
2016-08-24
Last Posted Date
2016-08-24
Lead Sponsor
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Target Recruit Count
75
Registration Number
NCT02877212
Locations
🇵🇰

Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Punjab, Pakistan

ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP

Completed
Conditions
Immune Thrombocytopenia
Interventions
Drug: Second Line ITP agents
First Posted Date
2013-10-29
Last Posted Date
2020-05-21
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
120
Registration Number
NCT01971684
Locations
🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

and more 26 locations

Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)

Phase 2
Conditions
Thrombocytopenia
Interventions
Other: Steroid refractory ITP
First Posted Date
2010-07-15
Last Posted Date
2010-07-15
Lead Sponsor
Cooperative Study Group A for Hematology
Target Recruit Count
38
Registration Number
NCT01162941
Locations
🇰🇷

Asan Medical Center, Seoul, Asanbyeongwon-gil, songpa-gu, Korea, Republic of

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

Phase 3
Completed
Conditions
Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Interventions
Biological: AMG 531
Drug: Placebo
First Posted Date
2005-01-28
Last Posted Date
2022-11-07
Lead Sponsor
Amgen
Target Recruit Count
63
Registration Number
NCT00102323
© Copyright 2025. All Rights Reserved by MedPath